bioAffinity Technologies, Inc. announced on July 22, 2025, that the Canadian Patent Office has allowed its patent application related to a method for detecting lung disease through flow cytometry analysis of sputum. This patent strengthens the international protection of the company’s diagnostic platform, which powers its CyPath® Lung test.
The Canadian patent, Patent No. 3,136,245, titled 'System and Method for Determining Lung Health,' specifically protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum for identifying lung cancer cells. This intellectual property is crucial for safeguarding the company's technology.
Lung cancer is the leading cause of cancer death in Canada, with approximately 31,000 Canadians diagnosed and 20,700 deaths in 2024. This patent supports bioAffinity Technologies' efforts to build a global intellectual property footprint and potentially expand market access for CyPath® Lung in Canada, where early detection can significantly improve survival rates.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.